Search Within

Larry Wayne Buie

Formats
  1. Meeting Abstract (14)
  2. Journal Article (10)
  3. Review (1)
Groups
  1. Department of Medicine (18)
  2. Clinical Pharmacy Specialists (15)
  3. Hematologic Malignancies, Division of (14)
  4. Center for Hematologic Malignancies (11)
  5. Biostatistics Service (9)
  6. Epidemiology and Biostatistics (9)

More Groups

People
  1. Ryan Daley (7)
  2. Sean Devlin (6)
  3. Troy Horvat (6)
  4. Josiah Land (5)
  5. Dan Douer (4)
  6. Dazhi Liu (4)

More People

Years
  1. 2022 (3)
  2. 2021 (3)
  3. 2020 (3)
  4. 2019 (5)
  5. 2018 (2)
  6. 2017 (4)

More Years

Publications
  1. Blood (7)
  2. Biology of Blood and Marrow Transplantation (3)
  3. Annals of Pharmacotherapy (2)
  4. Journal of Oncology Pharmacy Practice (2)
  5. American Journal of Managed Care (1)
  6. Annals of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Elsevier Inc. (4)
  3. American Society of Clinical Oncology (3)
  4. Nature Publishing Group (2)
  5. Sage Publications (2)
  6. Sage Publications Ltd. (2)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Choice of hypomethylating agent (HMA) for initial treatment does not influence outcome or survival for therapy-related myeloid neoplasms (t-MN)
    Meeting Abstract

    Kabel, C. C.; Goldman, D. A.; Buie, L. W.; Klimek, V. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Busulfan/melphalan/fludarabine (Bu/Mel/Flu) conditioning versus total body irradiation/thiotepa/cyclophosphamide (HFTBI/Thio/Cy) based conditioning in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing CD34-selected T-cell depleted allogeneic stem cell transplantation (alloSCT)
    Meeting Abstract

    Orozco, J. S.; Hilden, P.; Maloy, M. A.; Pappacena, J.; Buie, L. W.; Shaffer, B. C.; Papadopoulos, E. B.; Jakubowski, A. A.; Bhatt, V.
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (allo-HCT)
    Meeting Abstract

    Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia
    Journal Article

    Horvat, T. Z.; Seddon, A. N.; Ogunniyi, A.; King, A. C.; Buie, L. W.; Daley, R. J.
    Annals of Pharmacotherapy (2018)

    Fulltext@MSK | Save
  • More intensive fludarabine/busulfan (Flu/Bu) conditioning regimens result in similar outcomes without adding serious toxicity when compared to fludarabine/melphalan (Flu/Mel) in patients undergoing allogeneic hematopoietic cell transplant (Allo-HCT)
    Meeting Abstract

    Pappacena, J.; Bhatt, V.; Shah, G. L.; Hilden, P.; Maloy, M.; Buie, L. W.; Giralt, S. A.; Scordo, M.
    Blood (2017)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells
    Meeting Abstract

    Dixon, B. N.; Daley, R. J.; Horvat, T. Z.; Buie, L. W.; Hsu, M.; Latcha, S.; Brentjens, R. J.; Park, J. H.
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic factors and outcomes of patients with central nervous system (CNS) metastatic ALK-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kachur, E.; Reiss, S.; Land, J.; Buie, L.; Reiner, A.; Panageas, K.; Riely, G.; Pentsova, E.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save